SCHEMBL2649941

SCHEMBL2649941

CCCCCc1c(C(C)C)nc(C(C)C)c(CO)c1-c1ccccc1C(F)(F)F

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 20/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648175 0.85 GCGR (1.00) GCGR
SCHEMBL2649010 0.84 GCGR (0.80) GCGR
SCHEMBL2647205 0.83 GCGR (1.00) GCGR
SCHEMBL2648082 0.83 GCGR (0.83) GCGR
SCHEMBL2648515 0.82 GCGR (0.98) GCGR
SCHEMBL2648932 0.81 GCGR (0.48) GCGR
SCHEMBL27563102 0.81 GCGR (0.77) GCGR
SCHEMBL2647927 0.81 GCGR (0.73) GCGR
SCHEMBL2649275 0.80 GCGR (0.93) GCGR
SCHEMBL2648601 0.80 GCGR (0.71) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed